Loading...
Market
Which region will first use SmartFlow Cannula outside the US by 2025?
2
Resolution / Starting Odds
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
Official announcements from ClearPoint Neuro or regulatory bodies in respective regions
Story
ClearPoint Neuro ($CLPT) Gains FDA Approval for SmartFlow Cannula, First Direct Gene Therapy Delivery to Brain, Shares Up 10.9%
Nov 14, 2024, 01:20 PM
ClearPoint Neuro, trading under the ticker symbol $CLPT, has received FDA De Novo marketing authorization for its SmartFlow Cannula, marking a significant advancement in the delivery of gene therapy directly to the brain. This approval is particularly notable as it represents the first direct local delivery of neurological gene therapy in the United States, aimed at treating severe diseases, primarily affecting young children. The stock has seen a positive response, with a pre-market increase of 10.9%. The authorization is expected to open up new opportunities in the field of gene therapy, potentially transforming treatment options for patients suffering from debilitating conditions.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Europe • 25%
Asia • 25%
Africa • 25%
South America • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
UK • 25%
Germany • 25%
Canada • 25%
Other • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Canada • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%